Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2004 Sep;59(9):761–768. doi: 10.1136/thx.2003.013839

Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids

I Campbell 1, J Douglas 1, R Francis 1, R Prescott 1, D Reid 1
PMCID: PMC1747122  PMID: 15333852

Abstract

Background: Glucocorticoids are associated with a reduction in bone density and an increased risk of fracture. Concurrent treatment with bisphosphonates reduces bone loss and may prevent fractures. A randomised study was performed to determine whether treatment with cyclical etidronate and/or calcium for 5 years prevents fractures or reverses/reduces bone loss in patients receiving glucocorticoid treatment for asthma.

Methods: A multicentre, randomised, parallel group comparison of etidronate alone, calcium alone, etidronate + calcium, and no treatment, with stratification according to level of glucocorticoid exposure was carried out in 39 chest clinics in the UK. Three hundred and forty nine postmenopausal female and male outpatients with asthma aged 50–70 years were randomised. The main outcome measures were fractures and changes in bone mineral density (BMD).

Results: Overall, 8% of the patients experienced symptomatic fractures and 17.5% developed either a symptomatic fracture and/or a semiquantitative vertebral fracture by the end of 5 years There were no significant differences between the four treatment groups. Comparing etidronate with no etidronate, the rates of new fractures were not significantly different for symptomatic fractures (OR 1.07 (95% CI 0.46 to 2.47)) or for any fractures (OR 0.82 (95% CI 0.45 to 1.47)). For the comparison of calcium with no calcium the corresponding ORs were 1.43 (95% CI 0.62 to 3.33) and 0.91 (95% CI 0.50 to 1.63). In post hoc analysis the effect of etidronate was greater in women than in men (interaction p value 0.02) with the fracture incidence roughly halved (OR 0.39, 95% CI 0.14 to 0.99). Etidronate increased BMD at the lumbar spine by 4.1% (p = 0.001) while calcium had no significant effect. At the proximal femur the effects of treatment were not significant (relative increases etidronate 1.6%; calcium 1.1%). The rate of new fractures in patients with fractures at entry (23.7%) was higher than in those without fractures at entry (14.3%): OR 1.87 (95% CI 1.06 to 3.07). No association was found between change in BMD and new fractures.

Conclusions: In patients receiving glucocorticoids for asthma etidronate significantly increased BMD over 5 years at the lumbar spine but not at the hip and had little if any protective effect against fractures, except possibly in postmenopausal women. The effects of calcium were not significant. Combination treatment had no advantage but increased unwanted effects.

Full Text

The Full Text of this article is available as a PDF (117.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi J. D., Saag K. G., Delmas P. D., Liberman U. A., Emkey R. D., Seeman E., Lane N. E., Kaufman J. M., Poubelle P. E., Hawkins F. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001 Jan;44(1):202–211. doi: 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  2. Adachi J., Cranney A., Goldsmith C. H., Bensen W. G., Bianchi F., Cividino A., Craig G. L., Kaminska E., Sebaldt R. J., Papaioannou A. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol. 1994 Oct;21(10):1922–1926. [PubMed] [Google Scholar]
  3. Adinoff A. D., Hollister J. R. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med. 1983 Aug 4;309(5):265–268. doi: 10.1056/NEJM198308043090502. [DOI] [PubMed] [Google Scholar]
  4. CURTISS P. H., Jr, CLARK W. S., HERNDON C. H. Vertebral fractures resulting from prolonged cortisone and corticotropin therapy. J Am Med Assoc. 1954 Oct 2;156(5):467–469. doi: 10.1001/jama.1954.02950050007002. [DOI] [PubMed] [Google Scholar]
  5. Cranney A., Guyatt G., Krolicki N., Welch V., Griffith L., Adachi J. D., Shea B., Tugwell P., Wells G., Osteoporosis Research Advisory Group (ORAG) A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2001;12(2):140–151. doi: 10.1007/s001980170147. [DOI] [PubMed] [Google Scholar]
  6. Cranney Ann, Guyatt Gordon, Griffith Lauren, Wells George, Tugwell Peter, Rosen Clifford, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002 Aug;23(4):570–578. doi: 10.1210/er.2001-9002. [DOI] [PubMed] [Google Scholar]
  7. Crooks S. W., Colman S. B., Campbell I. A. Costs and getting ethical approval deter doctors from participating in multicentre trials. BMJ. 1996 Jun 29;312(7047):1669–1669. doi: 10.1136/bmj.312.7047.1669a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Egan J. J., Maden C., Kalra S., Adams J. E., Eastell R., Woodcock A. A. A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years. Eur Respir J. 1999 Jun;13(6):1267–1275. [PubMed] [Google Scholar]
  9. Genant H. K., Grampp S., Glüer C. C., Faulkner K. G., Jergas M., Engelke K., Hagiwara S., Van Kuijk C. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res. 1994 Oct;9(10):1503–1514. doi: 10.1002/jbmr.5650091002. [DOI] [PubMed] [Google Scholar]
  10. Genant H. K., Li J., Wu C. Y., Shepherd J. A. Vertebral fractures in osteoporosis: a new method for clinical assessment. J Clin Densitom. 2000 Fall;3(3):281–290. doi: 10.1385/jcd:3:3:281. [DOI] [PubMed] [Google Scholar]
  11. Hubbard Richard B., Smith Chris J. P., Smeeth Liam, Harrison Tim W., Tattersfield Anne E. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med. 2002 Sep 25;166(12 Pt 1):1563–1566. doi: 10.1164/rccm.200206-606OC. [DOI] [PubMed] [Google Scholar]
  12. Israel E., Banerjee T. R., Fitzmaurice G. M., Kotlov T. V., LaHive K., LeBoff M. S. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med. 2001 Sep 27;345(13):941–947. doi: 10.1056/NEJMoa002304. [DOI] [PubMed] [Google Scholar]
  13. Koster J. C., Hackeng W. H., Mulder H. Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women. Eur J Clin Pharmacol. 1996;51(2):145–147. doi: 10.1007/s002280050175. [DOI] [PubMed] [Google Scholar]
  14. Lindsay R., Silverman S. L., Cooper C., Hanley D. A., Barton I., Broy S. B., Licata A., Benhamou L., Geusens P., Flowers K. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001 Jan 17;285(3):320–323. doi: 10.1001/jama.285.3.320. [DOI] [PubMed] [Google Scholar]
  15. Luengo M., Picado C., Del Rio L., Guañabens N., Montserrat J. M., Setoain J. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax. 1991 Nov;46(11):803–806. doi: 10.1136/thx.46.11.803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lukert B. P., Raisz L. G. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990 Mar 1;112(5):352–364. doi: 10.7326/0003-4819-112-5-352. [DOI] [PubMed] [Google Scholar]
  17. Matsumoto H., Ishihara K., Hasegawa T., Umeda B., Niimi A., Hino M. Effects of inhaled corticosteroid and short courses of oral corticosteroids on bone mineral density in asthmatic patients : a 4-year longitudinal study. Chest. 2001 Nov;120(5):1468–1473. doi: 10.1378/chest.120.5.1468. [DOI] [PubMed] [Google Scholar]
  18. Medici T. C., Grebski E., Häcki M., Rüegsegger P., Maden C., Efthimiou J. Effect of one year treatment with inhaled fluticasone propionate or beclomethasone dipropionate on bone density and bone metabolism: a randomised parallel group study in adult asthmatic subjects. Thorax. 2000 May;55(5):375–382. doi: 10.1136/thorax.55.5.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mulder H., Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol. 1994 Apr;33(4):348–350. doi: 10.1093/rheumatology/33.4.348. [DOI] [PubMed] [Google Scholar]
  20. Packe G. E., Douglas J. G., McDonald A. F., Robins S. P., Reid D. M. Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids. Thorax. 1992 Jun;47(6):414–417. doi: 10.1136/thx.47.6.414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Peat I. D., Healy S., Reid D. M., Ralston S. H. Steroid induced osteoporosis: an opportunity for prevention? Ann Rheum Dis. 1995 Jan;54(1):66–68. doi: 10.1136/ard.54.1.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Pitt P., Li F., Todd P., Webber D., Pack S., Moniz C. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment. Thorax. 1998 May;53(5):351–356. doi: 10.1136/thx.53.5.351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Reid I. R., Heap S. W., King A. R., Ibbertson H. K. Two-year follow-up of biphosphonate (APD) treatment in steroid osteoporosis. Lancet. 1988 Nov 12;2(8620):1144–1144. doi: 10.1016/s0140-6736(88)90566-1. [DOI] [PubMed] [Google Scholar]
  24. Reid I. R., King A. R., Alexander C. J., Ibbertson H. K. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet. 1988 Jan 23;1(8578):143–146. doi: 10.1016/s0140-6736(88)92721-3. [DOI] [PubMed] [Google Scholar]
  25. Ross P. D., Davis J. W., Epstein R. S., Wasnich R. D. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991 Jun 1;114(11):919–923. doi: 10.7326/0003-4819-114-11-919. [DOI] [PubMed] [Google Scholar]
  26. Roux C., Oriente P., Laan R., Hughes R. A., Ittner J., Goemaere S., Di Munno O., Pouillès J. M., Horlait S., Cortet B. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab. 1998 Apr;83(4):1128–1133. doi: 10.1210/jcem.83.4.4742. [DOI] [PubMed] [Google Scholar]
  27. Selby P. L., Halsey J. P., Adams K. R., Klimiuk P., Knight S. M., Pal B., Stewart I. M., Swinson D. R. Corticosteroids do not alter the threshold for vertebral fracture. J Bone Miner Res. 2000 May;15(5):952–956. doi: 10.1359/jbmr.2000.15.5.952. [DOI] [PubMed] [Google Scholar]
  28. Storm T., Thamsborg G., Steiniche T., Genant H. K., Sørensen O. H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990 May 3;322(18):1265–1271. doi: 10.1056/NEJM199005033221803. [DOI] [PubMed] [Google Scholar]
  29. Struys A., Snelder A. A., Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med. 1995 Sep;99(3):235–242. doi: 10.1016/s0002-9343(99)80154-5. [DOI] [PubMed] [Google Scholar]
  30. Van Staa T. P., Laan R. F., Barton I. P., Cohen S., Reid D. M., Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003 Nov;48(11):3224–3229. doi: 10.1002/art.11283. [DOI] [PubMed] [Google Scholar]
  31. Van Staa T. P., Leufkens H. G., Abenhaim L., Zhang B., Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000 Jun;15(6):993–1000. doi: 10.1359/jbmr.2000.15.6.993. [DOI] [PubMed] [Google Scholar]
  32. Wallach S., Cohen S., Reid D. M., Hughes R. A., Hosking D. J., Laan R. F., Doherty S. M., Maricic M., Rosen C., Brown J. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000 Oct;67(4):277–285. doi: 10.1007/s002230001146. [DOI] [PubMed] [Google Scholar]
  33. Walsh L. J., Wong C. A., Pringle M., Tattersfield A. E. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ. 1996 Aug 10;313(7053):344–346. doi: 10.1136/bmj.313.7053.344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Watts N. B., Harris S. T., Genant H. K., Wasnich R. D., Miller P. D., Jackson R. D., Licata A. A., Ross P., Woodson G. C., 3rd, Yanover M. J. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990 Jul 12;323(2):73–79. doi: 10.1056/NEJM199007123230201. [DOI] [PubMed] [Google Scholar]
  35. Wisniewski A. F., Lewis S. A., Green D. J., Maslanka W., Burrell H., Tattersfield A. E. Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma. Thorax. 1997 Oct;52(10):853–860. doi: 10.1136/thx.52.10.853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Wong C. A., Walsh L. J., Smith C. J., Wisniewski A. F., Lewis S. A., Hubbard R., Cawte S., Green D. J., Pringle M., Tattersfield A. E. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet. 2000 Apr 22;355(9213):1399–1403. doi: 10.1016/S0140-6736(00)02138-3. [DOI] [PubMed] [Google Scholar]
  37. van Staa T. P., Leufkens H. G., Abenhaim L., Zhang B., Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000 Dec;39(12):1383–1389. doi: 10.1093/rheumatology/39.12.1383. [DOI] [PubMed] [Google Scholar]
  38. van Staa T. P., Leufkens H. G., Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res. 2001 Mar;16(3):581–588. doi: 10.1359/jbmr.2001.16.3.581. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES